E-LIB Suche - Ergebnisse für: Lieu, C H

1

Toward optimizing patient selection for EGFR antibody thera..:

Emmett, M.J. ; Quintanilha, J.C.F. ; Graf, R.P....
ESMO Real World Data and Digital Oncology. 4 (2024) - p. 100036 , 2024

Link: https://doi.org/10.1016/..

2

Crizotinib in patients with tumors harboring ALK or ROS1 re..:

Mansfield, A. S. ; Wei, Z. ; Mehra, R....
npj Precision Oncology. 6 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

3

Outcome of neoadjuvant treatment for pancreatic cancer in e..:

Oba, A ; Wu, Y H A ; Lieu, C H...
British Journal of Surgery. 108 (2021) 8 - p. 976-982 , 2021

Link: https://doi.org/10.1093/..

4

Improved Survival With External Beam Radiation Therapy for ..:

Rusthoven, C.G. ; Amini, A. ; Yeh, N....
International Journal of Radiation Oncology*Biology*Physics. 93 (2015) 3 - p. E168 , 2015

Link: https://doi.org/10.1016/..

5

Cytokine profile and prognostic significance of high neutro..:

Chen, Z-Y ; Raghav, K ; Lieu, C H...
British Journal of Cancer. 112 (2015) 6 - p. 1088-1097 , 2015

Link: https://doi.org/10.1038/..

6

From Bench to Bedside: Lessons Learned in Translating Precl..:

Lieu, C. H. ; Tan, A.-C. ; Leong, S...
JNCI Journal of the National Cancer Institute. 105 (2013) 19 - p. 1441-1456 , 2013

Link: https://doi.org/10.1093/..

7

393 TAK-733, an Investigational Novel MEK Inhibitor, Suppre..:

Lieu, C.H. ; Tentler, J.L. ; Tan, A.C....
European Journal of Cancer. 48 (2012) - p. 119-120 , 2012

Link: https://doi.org/10.1016/..

8

Prevalence of the JAK2‐V617F mutation in Taiwanese patients..:

Lieu, C.‐H. ; Wu, H.‐S. ; Hon, Y.‐C....
Internal Medicine Journal. 38 (2008) 6a - p. 422-426 , 2008

Link: https://doi.org/10.1111/..

9

A dose-ranging study of the pharmacokinetics and pharmacody..:

O'Bryant, C. L. ; Lieu, C. H. ; Leong, S....
Cancer Chemotherapy and Pharmacology. 63 (2008) 3 - p. 477-489 , 2008

Link: https://doi.org/10.1007/..

10

Crizotinib in patients with tumors harboring ALK or ROS1 re..:

Mansfield, A S ; Wei, Z ; Mehra, R...
https://jdc.jefferson.edu/medoncfp/178. , 2022

Link: https://jdc.jefferson.ed..

11

Crizotinib in patients with tumors harboring ALK or ROS1 re..:

Mansfield, A S ; Wei, Z ; Mehra, R...
NPJ Precision Oncology. , 2022

Link: http://hdl.handle.net/10..

12

Crizotinib in patients with tumors harboring ALK or ROS1 re..:

Mansfield, A. S ; Wei, Z ; Mehra, R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888601/. , 2022

Link: http://www.ncbi.nlm.nih...

13

Cytokine profile and prognostic significance of high neutro..:

Chen, Z-Y ; Raghav, K ; Lieu, C H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366901/. , 2015

Link: http://www.ncbi.nlm.nih...

14

A dose-ranging study of the pharmacokinetics and pharmacody..:

O'Bryant, C. L ; Lieu, C. H ; Leong, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814254. , 2008

Link: http://www.ncbi.nlm.nih...

15

CEA-CD3 bispecific antibody cibisatamab with or without ate..:

Segal, Neil H. ; Melero, Ignacio ; Moreno, Victor...
Nature Communications. 15 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..